Regeneron Drug Approved to Help Prevent Severe COVID in Vulnerable After Exposure

WEDNESDAY, Aug. 4, 2021 (HealthDay News)

A preventive monoclonal antibody injection for people at high risk for developing severe COVID-19 after exposure to the coronavirus has been approved by the U.S. Food and Drug Administration.

The first dose of Regeneron’s cocktail must be injected within 96 hours of exposure to the coronavirus, the FDA said in a statement.

It contains the monoclonal antibodies casirivimab and imdevimab and is the first injectable coronavirus antibody treatment approved by the FDA to prevent COVID-19 after exposure to the virus, NBC News reported.

However, the treatment should not be considered a substitute for vaccination and anyone who is eligible should get vaccinated, the FDA…

Continue Reading

News Source:

Previous Story

Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial

Next Story

The Bigger the City, the Lower the Depression Rates?